JUPITER, Fla.--(BUSINESS WIRE)--Envoy Therapeutics, Inc., a drug discovery company, today announced that it has been awarded a second grant from The Michael J. Fox Foundation (MJFF). The additional funding will enable the continued development of compounds that selectively act on the motor circuitry that is compromised in Parkinson’s disease (PD) via modulation of a receptor target identified by Envoy. Further validation of the functional role of this biological target is intended to pave the way for the progression of compounds through preclinical development and eventually to improved treatment options for PD patients.
